- Home
- HG vs CNTA Comparison
HG vs CNTA Comparison
Compare HG & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HG | CNTA |
|---|---|---|
| Founded | 2013 | 2020 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 6.1B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HG | CNTA |
|---|---|---|
| Price | $30.40 | $39.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $32.00 | ★ $43.17 |
| AVG Volume (30 Days) | 435.5K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 6.26% | N/A |
| EPS Growth | ★ 51.23 | 29.13 |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $2,905,524,000.00 | $15,000,000.00 |
| Revenue This Year | $1.80 | N/A |
| Revenue Next Year | $12.52 | N/A |
| P/E Ratio | $23.43 | ★ N/A |
| Revenue Growth | ★ 24.70 | N/A |
| 52 Week Low | $20.47 | $10.95 |
| 52 Week High | $33.72 | $40.26 |
Technical Indicators
Market Signals| Indicator | HG | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 71.47 |
| Support Level | $29.70 | $39.36 |
| Resistance Level | $32.08 | $39.86 |
| Average True Range (ATR) | 0.87 | 0.10 |
| MACD | -0.11 | -0.20 |
| Stochastic Oscillator | 28.72 | 68.75 |
Price Performance
Historical ComparisonAbout HG Hamilton Insurance Group Ltd. Class B
Hamilton Insurance Group Ltd is a specialty insurance and reinsurance company. It operates globally, with underwriting operations in London, Dublin, Bermuda, and the United States. It operates three principal underwriting platforms (Hamilton Global Specialty, Hamilton Select and Hamilton Re) that are categorized into two reporting business segments: International and Bermuda.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.